Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 163 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

NCT07003984
Conditions
Chikungunya Virus
Interventions
CHIKV VLP vaccine, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
1 Year to 11 Years
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
8
States / cities
Fountain Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more
Conditions
Healthy Volunteers
Interventions
Febuxostat XR, Maalox Advance Regular Strength liquid
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Conditions
Schistosomiasis
Interventions
Placebo, Sm-TSP-2/Alhydrogel, Sm-TSP-2/Alhydrogel/GLA-AF
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bivalent Norovirus Vaccine Study

NCT01168401
Conditions
Gastroenteritis
Interventions
NoV GI.1/GII.4 Bivalent VLP Vaccine, Saline
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
3
States / cities
Silver Springs, Maryland • St Louis, Missouri • Rochester, New York
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization

NCT03455309
Conditions
Staphylococcus Aureus
Interventions
NDV-3A, Placebo
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
17 Years to 35 Years · Male only
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fort Benning, Georgia
Recruiting Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of wSp Vaccine in Young Children

NCT07216430
Conditions
Acute Otitis Media (AOM)
Interventions
wSp vaccine, Saline (0.9% NaCl)
Biological
Lead sponsor
Serum Life Science Europe GmbH
Industry
Eligibility
5 Months to 7 Months
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
7
States / cities
Pittsford, New York • Rochester, New York
Conditions
HIV-1-infection
Interventions
3M-052-AF + Alum, UVAX-1107, UVAX-1197
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
4
States / cities
Birmingham, Alabama • New York, New York • Rochester, New York + 1 more
Conditions
Type 1 Diabetes Mellitus
Interventions
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU, Placebo
Biological · Dietary Supplement
Lead sponsor
Diamyd Medical AB
Industry
Eligibility
12 Years to 28 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
13
States / cities
Newport Beach, California • Palo Alto, California • San Diego, California + 10 more
Conditions
Renal Failure
Interventions
calcium acetate, aluminum hydroxide, Sevelamer
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 3 Interventional Accepts healthy volunteers Results available

HerpeVac Trial for Young Women

NCT00057330
Conditions
Herpes Simplex Infection
Interventions
HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine, Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 30 Years · Female only
Enrollment
8,323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
Completed Phase 1 Interventional Accepts healthy volunteers

AMA1-C1/Alhydrogel + CpG 7909 for Malaria

NCT00344539
Conditions
Plasmodium Falciparum Malaria
Interventions
AMA1-C1/Alhydrogel®, CPG 7909 Oligodeoxynucleotide (VaxImmune®)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, New York
Completed Phase 1 Interventional Accepts healthy volunteers Results available

VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults

NCT03879603
Conditions
Venezuelan Equine Encephalitis, Western Equine Encephalitis, Eastern Equine Encephalitis, Alphavirus Infections
Interventions
VRC-WEVVLP073-00-VP, VRC-GENMIX083-AL-VP
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Decatur, Georgia
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial

NCT01011335
Conditions
Staphylococcus Aureus
Interventions
Monovalent rAT, Monovalent rLukS-PV, Bivalent rLukS-PV / rAT, Placebo with adjuvant, Placebo
Biological
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Fort Sam Houston, Texas • Portsmouth, Virginia
Conditions
Clostridium Difficile Immunisation, Diphtheria, Diphtheria Immunisation, Pertussis, Tetanus, Tetanus Immunisation
Interventions
Tetanus and Diphtheria Toxoids Adsorbed, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
399 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Pitt Hopkins Syndrome
Interventions
MTP-101P, Vancomycin, Magnesium Citrate, Antacid, Placebo MTP-101P, Placebo Vancomycin
Combination Product
Lead sponsor
Gut-Brain-Axis Therapeutics Inc.
Other
Eligibility
5 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Prostate Cancer
Interventions
rsPSMA protein plus Alhydrogel® vaccine
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Trial of Inactivated West Nile Virus Vaccine

NCT02337868
Conditions
West Nile Viral Infection
Interventions
HydroVax-001, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Chikungunya Virus Infection
Interventions
CHIKV VLP vaccine booster, Placebo booster
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
12 Years and older
Enrollment
715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
24
States / cities
Mobile, Alabama • Tempe, Arizona • Melbourne, Florida + 20 more
Conditions
Malaria
Interventions
AMA1/Alhydrogel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

NCT04722003
Conditions
Gonorrhoea
Interventions
Meningococcal Group B Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Conditions
Staphylococcus (S.) Aureus Infection
Interventions
LTB-SA7, Placebo
Biological
Lead sponsor
LimmaTech Biologics AG
Industry
Eligibility
18 Years to 50 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults

NCT06745921
Conditions
West Nile Viral Infection
Interventions
HydroVax-001B WNV, Placebo, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
HIV Infections
Interventions
Aluminum hydroxide, MF59, rgp120/HIV-1IIIB, rgp120/HIV-1MN, rgp120/HIV-1 SF-2, Env 2-3
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • San Jose, California + 5 more
Conditions
Healthy Volunteers
Interventions
Purified Inactivated Zika Virus Vaccine (PIZV), Placebo
Biological · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
5
States / cities
Oakland Park, Florida • Meridian, Idaho • Wichita, Kansas + 2 more